BOLD Boundless Bio, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 7, 2026
$2.62
· of 52w range
· above low
· to high
$1.0052w low
$3.1652w high
Market Cap (MRQ)
$59M
P/E
-1.0
EPS
$-2.60
your badges
52W Range
$1–$3
Analyst Rating
HOLD
Price Target
$4
P/E
-1.0
ROE
-46.7%
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
BOLD Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$2.62
Market Cap (MRQ)
$59M
P/E
-1.0
EPS
$-2.60
ROE
-46.7%
52W Range
$1–$3
BOLD Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About Boundless Bio, Inc. - Common Stock Company overview from Wikipedia
sectorHealthcare
industryBiotechnology
employees28
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
EPS$-2.602023-12-31 → 2025-12-31
Free Cash Flow$-47M2024-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | BOLD | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -1.0 | · | · | · | |
| P/B (MRQ) | 0.9 | · | 1.6 | Undervalued | |
| Price / FCF (TTM) | -1.0 | · | · | · | |
| Price / Cash Flow (TTM) | -1.0 | · | · | · | |
| Price / Tangible Book | 0.6 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | BOLD | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| ROA | -32.0% | · | -106.0% | Top tier | |
| ROE | -46.7% | · | -116.7% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | BOLD | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 9.5 | · | 3.9 | Strong liquidity | |
| Quick Ratio | 8.6 | · | 3.2 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-12.9%
Next Report
Nov 03, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 17, 2026 | $-1.06 | $-0.59 | -79.2% |
| March 31, 2026 | May 18, 2026 | $-0.60 | $-0.59 | -2.0% |
| Dec. 31, 2025 | $-0.58 | $-0.53 | -9.4% | |
| Sept. 30, 2025 | $-0.62 | $-0.59 | -4.3% | |
| June 30, 2025 | $-0.70 | $-0.66 | -5.6% | |
| March 31, 2025 | $-0.71 | $-0.75 | 5.3% | |
| Dec. 31, 2024 | $-0.74 | $-0.78 | 4.8% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| R&D Expense | $45M | $55M | $43M | |
| SG&A Expense | $19M | $18M | $12M | |
| Operating Expenses | $64M | $73M | $55M | |
| Operating Income | $-64M | $-73M | $-55M | |
| Interest Income | $5M | $8M | $5M | |
| Other Non-op | $-2.0K | $12.0K | $80.0K | |
| Income Tax | $0 | $0 | · | |
| Net Income | $-58M | $-65M | $-49M | |
| EPS (Basic) | $-2.60 | $-3.85 | $-40.65 | |
| EPS (Diluted) | $-2.60 | $-3.85 | $-40.65 | |
| Shares (Basic) | 22,360,000 | 16,984,000 | 1,216,000 | |
| Shares (Diluted) | 22,360,000 | 16,984,000 | 1,216,000 | |
| EBITDA | $-62M | $-72M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & Equivalents | $18M | $27M | $24M | |
| Short-term Investments | $90M | $126M | $97M | |
| Prepaid Expense | $2M | $2M | $3M | |
| Current Assets | $110M | $154M | $124M | |
| PP&E (Net) | $3M | $4M | $3M | |
| PP&E (Gross) | $8M | $8M | $5M | |
| Accum. Depreciation | $5M | $4M | $3M | |
| Total Assets | $157M | $206M | $130M | |
| Accounts Payable | $1M | $1M | $2M | |
| Current Liabilities | $13M | $8M | $9M | |
| Capital Leases | $46M | $48M | · | |
| Total Liabilities | $58M | $56M | $9M | |
| Common Stock | $2.0K | $2.0K | $0 | |
| Paid-in Capital | $358M | $352M | $9M | |
| Retained Earnings | $-260M | $-201M | $-136M | |
| AOCI | $64.0K | $121.0K | $40.0K | |
| Stockholders' Equity | $99M | $151M | $-127M | |
| Liabilities + Equity | $157M | $206M | $130M | |
| Shares Outstanding | 22,407,000 | 22,300,000 | 1,248 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| D&A | $1M | $1M | $957.0K | |
| Stock-based Comp | $6M | $8M | $3M | |
| Deferred Tax | $0 | · | · | |
| Other Non-cash | $4M | $-4M | · | |
| Operating Cash Flow | $-47M | $-61M | $-47M | |
| CapEx | $546.0K | $3M | $633.0K | |
| Investing Cash Flow | $38M | $-26M | $-38M | |
| Financing Cash Flow | $141.0K | $90M | $98M | |
| Net Change in Cash | $-9M | $3M | $13M | |
| Free Cash Flow | $-47M | $-63M | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| ROA | -32.0% | -38.9% | · | |
| ROE | -46.7% | -554.9% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Current Ratio | 8.7 | 19.0 | · | |
| Quick Ratio | 8.6 | 18.7 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Book Value / Share | $4.40 | $6755.25 | · | |
| Cash Flow / Share | $-2.09 | $-3.58 | · | |
| Cash / Share | $0.80 | $1192.24 | · | |
| EPS (TTM) | $-2.60 | $-3.85 | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net Income TTM | $-58M | $-65M | · | |
| Market Cap | $27M | $64.7K | · | |
| P/E | -0.5 | -0.8 | · | |
| P/B | 0.3 | 0.0 | · | |
| P / Tangible Book | 0.3 | 0.0 | · | |
| P / Cash Flow | -0.6 | -0.0 | · | |
| P / FCF | -0.6 | -0.0 | · | |
| Earnings Yield | -216.7% | -132.8% | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $14M | $10M | $10M | $11M | $12M | $12M | $13M | $14M | $15M | $13M | $10M | $12M | $11M | $10M | |
| SG&A Expense | $10M | $5M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $4M | $3M | $3M | $3M | $3M | |
| Operating Expenses | $24M | $14M | $14M | $15M | $17M | $17M | $18M | $19M | $19M | $17M | $14M | $15M | $14M | $12M | |
| Operating Income | $-24M | $-14M | $-14M | $-15M | $-17M | $-17M | $-18M | $-19M | $-19M | $-17M | $-14M | $-15M | $-14M | $-12M | |
| Interest Income | $690.0K | $920.0K | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $1M | $2M | $2M | $2M | $395.0K | |
| Other Non-op | $1.0K | · | $0 | $0 | $0 | $-2.0K | $-85.0K | $32.0K | $33.0K | $32.0K | $64.0K | $32.0K | $11.0K | $-27.0K | |
| Net Income | $-24M | $-14M | $-13M | $-14M | $-16M | $-16M | $-16M | $-17M | $-17M | $-15M | $-12M | $-13M | $-12M | $-12M | |
| EPS (Basic) | $-1.06 | $-0.60 | $-0.57 | $-0.62 | $-0.70 | $-0.71 | $9.93 | $-0.74 | $-0.77 | $-12.27 | $-9.75 | $-10.71 | $-10.28 | $-9.91 | |
| EPS (Diluted) | $-1.06 | $-0.60 | $-0.57 | $-0.62 | $-0.70 | $-0.71 | $9.93 | $-0.74 | $-0.77 | $-12.27 | $-9.75 | $-10.71 | $-10.28 | $-9.91 | |
| Shares (Basic) | 22,450,000 | 22,407,000 | · | 22,386,000 | 22,356,000 | 22,300,000 | · | 22,254,000 | 22,023,000 | 1,258,000 | · | 1,230,000 | 1,206,000 | 1,183,000 | |
| Shares (Diluted) | 22,450,000 | 22,407,000 | · | 22,386,000 | 22,356,000 | 22,300,000 | · | 22,254,000 | 22,023,000 | 1,258,000 | · | 1,230,000 | 1,206,000 | 1,183,000 | |
| EBITDA | $-24M | $-14M | · | $-15M | $-17M | $-17M | · | $-19M | $-19M | $-17M | · | · | · | · |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20M | $17M | $18M | $15M | $15M | $15M | $27M | $40M | $31M | $25M | $24M | · | · | · | |
| Short-term Investments | $52M | $75M | $90M | $103M | $112M | $123M | $126M | $127M | $148M | $80M | $97M | · | · | · | |
| Prepaid Expense | $1M | $2M | $2M | $3M | $3M | $2M | $2M | $3M | $4M | $7M | $3M | · | · | · | |
| Current Assets | $74M | $95M | $110M | $120M | $130M | $140M | $154M | $170M | $183M | $112M | $124M | · | · | · | |
| PP&E (Net) | $97.0K | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $4M | $2M | $3M | · | · | · | |
| PP&E (Gross) | $4M | $8M | $8M | $8M | $8M | $8M | $8M | $7M | $7M | $5M | $5M | · | · | · | |
| Accum. Depreciation | $3M | $5M | $5M | $5M | $4M | $4M | $4M | $4M | $3M | $3M | $3M | · | · | · | |
| Total Assets | $74M | $141M | $157M | $169M | $179M | $191M | $206M | $175M | $188M | $117M | $130M | · | · | · | |
| Accounts Payable | $1M | $2M | $1M | $1M | $2M | $1M | $1M | $3M | $2M | $3M | $2M | · | · | · | |
| Current Liabilities | $8M | $10M | $13M | $12M | $9M | $6M | $8M | $10M | $9M | $11M | $9M | · | · | · | |
| Capital Leases | $0 | $45M | $46M | $47M | $48M | $48M | $48M | · | · | · | · | · | · | · | |
| Total Liabilities | $8M | $55M | $58M | $59M | $57M | $55M | $56M | · | · | · | $9M | · | · | · | |
| Common Stock | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $0 | $0 | · | · | · | |
| Paid-in Capital | $363M | $360M | $358M | $357M | $356M | $354M | $352M | $350M | $348M | $10M | $9M | · | · | · | |
| Retained Earnings | $-297M | $-273M | $-260M | $-247M | $-233M | $-217M | $-201M | $-185M | $-169M | $-152M | $-136M | · | · | · | |
| AOCI | $-32.0K | $-23.0K | $64.0K | $50.0K | $-4.0K | $32.0K | $121.0K | $236.0K | $-64.0K | $-21.0K | $40.0K | · | · | · | |
| Stockholders' Equity | $66M | $86M | $99M | $110M | $123M | $137M | $151M | $165M | $179M | $-141M | $-127M | · | · | · | |
| Liabilities + Equity | $74M | $141M | $157M | $169M | $179M | $191M | $206M | $175M | $188M | $117M | $130M | · | · | · | |
| Shares Outstanding | 22,475,000 | 22,407,000 | 22,407,000 | 22,386,000 | 22,386,000 | 22,300,000 | 22,300,000 | 22,254,465 | 22,254,102 | 1,262,638 | 1,248 | · | · | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $284.0K | $307.0K | $310.0K | $317.0K | $317.0K | $296.0K | $262.0K | $265.0K | $263.0K | $247.0K | $200.0K | $200.0K | $200.0K | |
| Stock-based Comp | $3M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $1M | $911.0K | $883.0K | $927.0K | $615.0K | |
| Other Non-cash | · | $-3M | · | · | · | $-886.0K | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-21M | $-15M | $-10M | $-10M | $-12M | $-15M | $-16M | $-13M | $-16M | $-16M | $-12M | $-12M | $-11M | $-12M | |
| CapEx | $38.0K | $8.0K | $424.0K | $15.0K | $48.0K | $59.0K | $466.0K | $483.0K | $2M | $83.0K | $268.0K | $151.0K | $128.0K | $86.0K | |
| Investing Cash Flow | $23M | $15M | $13M | $10M | $11M | $3M | $2M | $22M | $-68M | $18M | $16M | $-8M | $-69M | $22M | |
| Financing Cash Flow | · | · | $24.0K | $0 | · | · | $113.0K | $-13.0K | $91M | $-924.0K | $-1M | $-447.0K | $100M | $31.0K | |
| Net Change in Cash | $2M | $-385.0K | $3M | $283.0K | $-420.0K | $-11M | $-14M | $9M | $6M | $1M | $3M | $-20M | $20M | $10M | |
| Free Cash Flow | · | $-15M | · | · | · | $-15M | · | · | · | $-16M | · | · | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -18.7% | -8.2% | · | -8.1% | -8.5% | -10.2% | · | -18.9% | -18.0% | -26.4% | · | · | · | · | |
| ROE | -25.1% | -12.2% | · | -10.1% | -10.4% | 686.3% | · | -20.0% | -18.9% | 21.9% | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.5 | 9.9 | · | 10.1 | 14.1 | 22.1 | · | 17.0 | 20.4 | 10.5 | · | · | · | · | |
| Quick Ratio | 9.3 | 9.7 | · | 9.9 | 13.8 | 21.8 | · | 16.7 | 20.0 | 9.9 | · | · | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.94 | $3.86 | · | $4.92 | $5.48 | $6.13 | · | $7.42 | $8.05 | $-111.82 | · | · | · | · | |
| Cash Flow / Share | · | $-0.67 | · | · | · | $-0.65 | · | · | · | $-12.54 | · | · | · | · | |
| Cash / Share | $0.90 | $0.78 | · | $0.67 | $0.66 | $0.68 | · | $1.81 | $1.41 | $19.91 | · | · | · | · | |
| EPS (TTM) | $-2.85 | $-2.49 | · | $7.90 | $7.78 | $7.71 | · | $-23.53 | $-33.50 | $-43.01 | · | · | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-64M | $-56M | · | $-62M | $-64M | $-66M | · | $-61M | $-58M | $-53M | · | · | · | · | |
| Market Cap | $56M | $25M | · | $28M | $23M | $34M | · | $77M | $86M | $18M | · | · | · | · | |
| P/E | -0.9 | -0.4 | · | 0.2 | 0.1 | 0.2 | · | -0.1 | -0.1 | -0.3 | · | · | · | · | |
| P/B | 0.9 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.5 | 0.5 | -0.1 | · | · | · | · | |
| P / Tangible Book | 0.9 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.5 | 0.5 | · | · | · | · | · | |
| P / Cash Flow | · | -1.6 | · | · | · | -2.3 | · | · | · | -1.1 | · | · | · | · | |
| Earnings Yield | -114.0% | -226.4% | · | 642.3% | 770.3% | 510.6% | · | -678.1% | -865.6% | -301.8% | · | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net Income | $-58M | $-65M | $-49M |
| Diluted EPS | $-2.60 | $-3.85 | $-40.65 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Current Ratio | 8.7 | 19.0 | · |
| Quick Ratio | 8.6 | 18.7 | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free Cash Flow | $-47M | $-63M | · |
Institutional owners (13F) 42 filers · $38.2M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
42
Value held
$38.2M
New positions
13
Exited positions
8
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 13 (+6 vs prior Q) | 8 (+2 vs prior Q) | 10 (+4 vs prior Q) | 9 (-1 vs prior Q) | +6.8M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| ARCH Venture Management, LLC | $6,735,238 | 2,694,095 | 17.63% | Shares |
| FMR LLC | $6,452,638 | 2,581,055 | 16.89% | Shares |
| TANG CAPITAL MANAGEMENT LLC | $6,399,688 | 2,559,875 | 16.75% | Shares |
| ADAR1 Capital Management, LLC | $4,920,540 | 1,968,216 | 12.88% | Shares |
| Cormorant Asset Management, LP | $2,500,000 | 1,000,000 | 6.54% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $1,537,308 | 614,923 | 4.02% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $1,390,583 | 556,233 | 3.64% | Shares |
| MILLENNIUM MANAGEMENT LLC | $1,196,598 | 478,639 | 3.13% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $1,178,925 | 471,570 | 3.09% | Shares |
| VANGUARD GROUP INC | $795,308 | 662,757 | 2.08% | Shares |
| Alyeska Investment Group, L.P. | $750,000 | 300,000 | 1.96% | Shares |
| Affinity Asset Advisors, LLC | $625,000 | 250,000 | 1.64% | Shares |
| RBF Capital, LLC | $500,000 | 200,000 | 1.31% | Shares |
| Ensign Peak Advisors, Inc | $399,588 | 159,835 | 1.05% | Shares |
| Stonepine Capital Management, LLC | $386,488 | 154,595 | 1.01% | Shares |
| CITADEL ADVISORS LLC | $362,623 | 145,049 | 0.95% | Shares |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $320,000 | 128,000 | 0.84% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $291,839 | 116,736 | 0.76% | Shares |
| BlackRock, Inc. | $221,239 | 88,495 | 0.58% | Shares |
| PRELUDE CAPITAL MANAGEMENT, LLC | $209,995 | 83,998 | 0.55% | Shares |
| Rangeley Capital, LLC | $185,000 | 74,000 | 0.48% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $162,840 | 65,136 | 0.43% | Shares |
| JANE STREET GROUP, LLC | $160,807 | 64,323 | 0.42% | Shares |
| SUPERSTRING CAPITAL MANAGEMENT LP | $138,390 | 55,356 | 0.36% | Shares |
| NORTHERN TRUST CORP | $87,060 | 34,824 | 0.23% | Shares |
| XTX Topco Ltd | $83,403 | 33,361 | 0.22% | Shares |
| Qube Research & Technologies Ltd | $50,518 | 20,207 | 0.13% | Shares |
| China Universal Asset Management Co., Ltd. | $42,250 | 16,900 | 0.11% | Shares |
| STATE STREET CORP | $39,905 | 15,962 | 0.10% | Shares |
| MORGAN STANLEY | $32,500 | 13,000 | 0.09% | Shares |
| Caitong International Asset Management Co., Ltd | $26,108 | 10,443 | 0.07% | Shares |
| Pure Financial Advisors, LLC | $25,250 | 10,100 | 0.07% | Shares |
| Tower Research Capital LLC (TRC) | $870 | 348 | 0.00% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $440 | 176 | 0.00% | Shares |
| JPMORGAN CHASE & CO | $439 | 179 | 0.00% | Shares |
| ACADIAN ASSET MANAGEMENT LLC | $365 | 146,757 | 0.00% | Shares |
| HRT FINANCIAL LP | $290 | 116,288 | 0.00% | Shares |
| GSA CAPITAL PARTNERS LLP | $181 | 72,353 | 0.00% | Shares |
| CWM, LLC | $9 | 8 | 0.00% | Shares |
| Financial Management Professionals, Inc. | $5 | 2 | 0.00% | Shares |
| UBS Group AG | $5 | 2 | 0.00% | Shares |
| SBI Securities Co., Ltd. | $5 | 2 | 0.00% | Shares |
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners IX, LLC, ARCH Venture Partners X, LLC, Robert Nelsen, Keith Crandell, Clinton Bybee, Kristina Burow, Steven Gillis | Oct. 29, 2024 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 15 insiders · 8 officers · 7 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Zachary Hornby | President & CEO | Jan. 23, 2026 A | · | 0 | 0 | $0 |
| Jami Rubin | Chief Financial Officer | Aug. 19, 2024 A | · | 0 | 0 | $0 |
| Robert Doebele | Chief Medical Officer | Jan. 23, 2026 A | · | 0 | 0 | $0 |
| Jessica Oien | Chief Legal Officer and Corporate Secretary | Jan. 23, 2026 A | · | 0 | 0 | $0 |
| Christian Hassig | Chief Scientific Officer | Jan. 23, 2026 A | · | 0 | 0 | $0 |
| David A Hinkle | Senior VP, Finance, Controller and Treasurer | Jan. 23, 2026 A | · | 0 | 0 | $0 |
| Klaus W. Wagner | Chief Medical Officer | Aug. 19, 2024 A | · | 0 | 0 | $0 |
| Neil Abdollahian | Chief Business Officer | Aug. 19, 2024 A | · | 0 | 0 | $0 |
| James Christensen | Director | June 15, 2026 A | · | 0 | 0 | $0 |
| Nancy Whiting | Director | June 15, 2026 A | · | 0 | 0 | $0 |
| Jennifer Lew | Director | June 15, 2026 A | · | 0 | 0 | $0 |
| Jonathan E Lim | Director | June 15, 2026 A | 550,915 | 0 | 0 | $0 |
| Christine Brennan | Director | June 23, 2025 A | · | 0 | 0 | $0 |
| Kristina Burow | Director | June 23, 2025 A | 1,181,766 | 0 | 0 | $0 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% owner | April 2, 2024 C | 556,233 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 3 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
BOLD Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 6 analysts
SELL
Median target
$4.00
+52.7%
0 0.0%
Strong Buy
0 0.0%
Buy
3 50.0%
Hold
1 16.7%
Sell
2 33.3%
Strong Sell
12-Month Price Target
1 analysts · 2026-09-30Mean target $4.00 +52.7%
Low$4.00
Mean$4.00
High$4.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| BOLD | $27M | -0.5 | · | · | -46.7% | · |
| INKT | · | -3.8 | 4.5% | -6931.8% | 63.4% | · |
| ACET | · | -0.5 | · | · | · | · |
| NMAD | · | · | · | · | · | · |
| KLRS | $193M | -3.0 | · | · | -65.8% | · |
| FRMM | · | · | · | -6881.3% | -368.1% | · |
| CLNN | $64M | · | -41.5% | -13086.5% | 200.2% | · |
| XLO | $3M | -0.2 | 589.9% | -80.0% | -165.5% | · |
| INMB | $41M | -0.8 | 257.1% | -91866.0% | -175.3% | · |
| EXOZ | $92M | -10.0 | · | · | -172.3% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 7, 2026